Inflammatory Bowel Disease Patients Clinical Trial
Official title:
Prevalance of non_ Alcoholic Fatty Liver Diseases in Patient With Inflammatory Bowel Diseases Attending Assiut University Hospitals
To assess the prevalance of non_alcoholic fatty liver diseases in inflammatory bowel disease patients and its relation to type of treatment given and disease severity
Inflammatory bowel diseases (IBD) including Crohns disease (CD) and ulcerative colitis (UC)
are chronic relapsing disorders that often require long-term therapy and follow up .
They are recognized for their complex pathophysiology that involves innate immune system
deregulation and altered microbiome in genetically predisposed individuals. Non-alcoholic
fatty liver disease (NAFLD) includes a wide spectrum of disorders, ranging from hepatic
steatosis (NAFL) to non-alcoholic steatohepatitis (NASH). NAFLD patients are at high risk for
liver fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). Also NAFLD is typically
associated with altered metabolism and metabolic syndrome (MetS).
;